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Effect of Spironolactone on Left Ventricular Mass and
Aortic Stiffness in Early-Stage Chronic Kidney Disease
A Randomized Controlled Trial
Nicola C. Edwards, BMBS,* Richard P. Steeds, MD,* Paul M. Stewart, PHD,† Charles J. Ferro, MD,‡
Jonathan N. Townend, MD*
Birmingham, United Kingdom
Objectives We sought to determine whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibi-
tors and angiotensin receptor blockers (ARBs) improves left ventricular mass and arterial stiffness in early-stage
chronic kidney disease (CKD).
Background Chronic kidney disease is associated with a high risk of cardiovascular disease and a high prevalence of left ven-
tricular hypertrophy and arterial stiffness that confer an adverse prognosis. It is believed that these abnormali-
ties are in part a result of activation of the renin-angiotensin-aldosterone system.
Methods After an active run-in phase with spironolactone 25 mg once daily, 112 patients with stage 2 and 3 CKD with
good blood pressure control (mean daytime ambulatory blood pressure 130/85 mm Hg) on established treat-
ment with ACE inhibitors or ARBs were randomized to continue spironolactone or to receive a matching placebo.
Left ventricular mass (cardiac magnetic resonance) and arterial stiffness (pulse wave velocity/analysis, aortic
distensibility) were measured before run in and after 40 weeks of treatment.
Results Compared with placebo, the use of spironolactone resulted in significant improvements in left ventricular mass
(14  13 g vs. 3  11 g, p  0.01), pulse wave velocity (0.8  1.0 m/s vs. 0.1  0.9 m/s, p  0.01),
augmentation index (5.2  6.1% vs. 1.4  5.9%, p  0.05), and aortic distensibility (0.69  0.86  103
mm Hg vs. 0.04  1.04  103 mm Hg, p  0.01).
Conclusions The use of spironolactone reduces left ventricular mass and improves arterial stiffness in early-stage CKD. These
effects suggest that aldosterone exerts adverse cardiovascular effects in CKD and that spironolactone is worthy
of further study as a treatment that could reduce adverse cardiovascular events. (Is Spironolactone Safe and
Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure; NCT00291720) (J Am Coll
Cardiol 2009;54:505–12) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.066t
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ehronic kidney disease (CKD) is a major public health
roblem affecting 10% of adults in developed countries
nd conferring a high risk of cardiovascular disease (1). The
ajor health risk for patients with CKD is not progression
o end-stage renal disease but an increased risk of death
rom nonrenal, predominantly cardiovascular disease (2).
ardiovascular risk in patients with CKD increases in a
raded inverse relationship with glomerular filtration rate
GFR), but even in patients with early-stage CKD cardio-
ascular risk is increased approximately 4-fold. We have
ecently shown major abnormalities of cardiovascular struc-
rom the Departments of *Cardiology, †Medicine, and ‡Nephrology, University
ospital Birmingham and University of Birmingham, Birmingham, United
ingdom. This work was supported by a project grant from the British Heart
oundation.d
Manuscript received October 26, 2008; revised manuscript received January 29,
009; accepted March 3, 2009.ure and function in this group of patients (3). Despite these
ndings, there is little available evidence on which to base
reatment; most trials (4) of therapy directed at reducing
ardiovascular risk have systematically excluded patients
ith CKD.
See page 513
The importance of the renin-angiotensin-aldosterone
ystem as a driver of progressive renal and cardiovascular
isease in patients with CKD is increasingly apparent (5,6).
oth angiotensin II and aldosterone exert numerous adverse
ardiovascular effects, including the development of left
entricular hypertrophy (LVH) and increased arterial stiff-
ess (7). Although angiotensin-converting enzyme (ACE)
nhibitors and angiotensin receptor blockers (ARBs) are
ffective in reducing the progression of renal and vascular
amage in patients with CKD, they do not result in
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rone production, a stimulus to
ventricular hypertrophy, fibrosis,
and vascular inflammation (8).
We hypothesized that in patients
with early-stage CKD, continu-
ing aldosterone production is an
important cause of LVH and in-
creased arterial stiffness (9,10),
which are powerful risk factors for
cardiovascular disease in the gen-
eral population (11,12) and are
highly prevalent and prognostically
important in CKD (13,14). The
CRIB (Chronic Renal Impair-
ment in Birmingham) 2 trial has
therefore examined the effect of
the addition of the aldosterone an-
tagonist spironolactone to ACE
inhibitors or ARBs on these prog-
nostic markers in a group of patients
with early (stage 2 and 3) CKD.
Methods
Study design and treatment regi-
men. The study was a single-
center, prospective, double-blind,
placebo-controlled, randomized in-
terventional trial that comprised a
4-week open-label run-in phase of
25 mg of spironolactone once daily,
after which patients were random-
ized to continue a further 36 weeks
of treatment with 25 mg of spirono-
lactone or to receive placebo.
etting and participants. Patients were recruited from renal
linics at a University teaching hospital in the United Kingdom
rom 2005 to 2007. Inclusion criteria were as follows: age 18 to
0 years, stage 2 (GFR 60 to 89 ml/min/1.73 m2 and evidence
f kidney damage for 3 months) or stage 3 (GFR 30 to 59
l/min/1.73 m2) CKD (15), treatment with an ACE inhibitor
nd/or ARB for at least 6 months, and controlled blood
ressure (mean daytime blood pressure on ambulatory moni-
oring130/85 mm Hg). Estimated glomerular filtration rate
eGFR) was measured by the 4-variable Modification of Diet
n Renal Disease formula with serum creatinine recalibrated to
e traceable to an isotope-derived mass spectroscopy method
16). Exclusion criteria were as follows: a history or other
vidence of angina, myocardial infarction, heart failure, cerebral
r peripheral vascular disease, diabetes mellitus, previous hy-
erkalemia, valvular heart disease, atrial fibrillation, renovascu-
ar disease, and anemia (hemoglobin 12 g/dl). The protocol
as approved by South Birmingham Local Research Ethics
ommittee, and all patients supplied written informed
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
Aug  aortic augmentation
pressure
Aug Ix  augmentation
index
Aug Ix 75  augmentation
index corrected for a heart
rate of 75 beats/min
CKD  chronic kidney
disease
CMR  cardiovascular
magnetic resonance
EDV  end-diastolic volume
eGFR  estimated
glomerular filtration rate
GFR  glomerular filtration
rate
hsCRP  high-sensitivity
C-reactive protein
LV  left
ventricle/ventricular
LVH  left ventricular
hypertrophy
PAC  plasma aldosterone
concentration
PWA  pulse-wave analysis
PWV  pulse-wave velocity
RV  right
ventricle/ventricularonsent. wPatients were assessed at baseline (before the run-in phase)
nd at the end of the study (week 40) with a clinical history and
xamination, 24-h ambulatory blood pressure monitoring,
ardiovascular magnetic resonance (CMR) imaging, and mea-
urement of pulse-wave velocity (PWV) and pulse-wave anal-
sis (PWA). Venous blood samples were also collected after 30
in of supine rest for routine hematology and biochemistry,
ipid profiles, and measurement of plasma renin, aldosterone,
nd angiotensin II. Urine samples were obtained for measure-
ent of albumin-creatinine ratio. Biochemical and safety
onitoring was performed at weeks 0, 1, 2, 4, 8, 16, 28, and
0. Patients were withdrawn if they developed serious hyper-
alemia, defined as a single serum potassium concentration
6.5 or6.0 mmol/l on urgent repeat sampling. Patients with
otassium levels between 5.5 and 5.9 mmol/l received spirono-
actone 25 mg on alternate days, and repeat blood samples were
aken 1 week later. An independent data and safety monitoring
oard monitored the progress of all aspects of the study.
lood pressure, PWA, and PWV. All subjects underwent
4-h ambulatory blood pressure monitoring (Meditech
BPM-04, PMS Instruments, Maidenhead, United King-
om) at baseline and at week 40. Office brachial blood
ressure also was recorded with the subject lying supine after
0, 20, and 30 min in the nondominant arm and a validated
scillometric sphygmomanometer (Dinamap Procare, GE
ealthcare, Hatfield, United Kingdom). Augmentation pres-
ure (Aug) and index (Aug Ix) were assessed noninvasively by
he use of radial artery waveforms obtained with a high-fidelity
icromanometer (SPC-301, Millar Instruments, Houston,
exas). The corresponding central waveform was generated
y the use of a validated transfer function (SphygmoCor,
tCor Medical, Sydney, Australia) (17,18). The Aug Ix was
orrected for a heart rate of 75 beats/min (Aug Ix 75) (18).
ortic PWV was measured by use of the same device by
equentially recording electrocardiogram-gated carotid and
emoral artery waveforms as described previously (19). All
easurements were made in triplicate and mean values used
n analysis.
ardiovascular magnetic resonance imaging. Cardiovas-
ular magnetic resonance imaging was performed on a 1.5-T
canner (Sonata Symphony, Siemens, Erlangen, Germany).
erial contiguous short axis cines were piloted from the vertical
ong axis and horizontal long axis of the right ventricle and left
entricle (electrocardiogram [ECG] gated, steady-state free
recession imaging [True-FISP]; temporal resolution 40 to 50
s, repetition time 3.2 ms, echo time 1.6 ms, flip angle 60°,
lice thickness 7 mm) in accordance with previously validated
ethodologies (20). Analysis was performed off-line (Argus
oftware, Siemens) by a single blinded observer (N.E.) for the
ssessment of ventricular volumes (end-diastole, end-systole,
troke volume), ejection fraction, and left ventricular (LV)
ass (20). Aortic distensibility was assessed in the ascending
orta at the level of the pulmonary artery and calculated by use
f standard formulas (21).
utcomes and follow-up. The study coprimary end points
ere change in LV mass and arterial stiffness measured by
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August 4, 2009:505–12 Spironolactone in Early CKDWV. Secondary end points were aortic distensibility, Aug
Ix, blood pressure, and albuminuria.
tatistical analysis. We calculated that a sample size of 90
atients assigned equally to the 2 treatment groups would
rovide 95% power to detect a change in LV mass of 10 g
SD 12 g) on CMR and 80% power to detect a change in
WV of 0.6 m/s (SD 1.0 m/s) with an alpha error of 0.05
n each case (22). Data are expressed as mean  SD (unless
tated) and were log-transformed as necessary. Treatment
roups were compared by the use of t tests or chi-square
ests (at baseline) and repeated measures analysis of variance
for changes over time). Adjustments for changes in mean
rterial pressure for parameters of arterial stiffness were
ased on linear regressions. Trend was assessed by the use of
he Jonckheere-Terpstra test. Independent predictors of
hanges in LV mass and arterial stiffness were determined
ith the use of multivariate regression models. Intraobserver
eproducibility was assessed by the use of intraclass corre-
ation coefficients (23).
esults
f 2,196 consecutive patients with nondiabetic CKD at-
ending nephrology outpatient clinics, 1,911 were not im-
ediately eligible for recruitment (46% were not on an
CE inhibitor or ARB, 29% had renovascular disease or
ncontrolled hypertension, 15% had previous cardiovascular
vents, 2% had atrial fibrillation, and 8% other). Of the 285
atients who met the inclusion criteria, 170 patients de-
lined to participate; therefore, 115 patients were enrolled.
hree patients did not complete the run-in phase as
escribed in the following text. One hundred twelve pa-
atient Characteristics at BaselineTable 1 Patient Characteristics at Baseline
Placebo
(n  56)
Spironolactone
(n  56)
Age (yrs) 53 12 54 12
Male, n (%) 33 (59) 32 (57)
Office SBP (mm Hg) 130 19 130 16
Office DBP (mm Hg) 77 10 77 10
Serum creatinine (mg/dl) 1.4 0.38 1.5 0.39
eGFR (ml/min/1.73 m2) 53 11 49 12
Heart rate (beats/min) 65 11 66 12
Hemoglobin (g/dl) 13.5 1.6 13.5 1.3
Cholesterol (mg/dl) 181.5 42.5 189.2 42.5
Serum potassium (mmol/l) 4.3 0.3 4.4 0.8
Number of patients on treatment with
ACE inhibitors 39 38
Angiotensin-receptor blockers 19 19
Beta-blockers 8 15
Calcium-channel blockers 17 13
Statins 17 27
Diuretics 13 18
alues aremean SD unless otherwise indicated. There were no significant differences in baseline
haracteristics.a
ACE  angiotensin-converting enzyme; DBP  diastolic blood pressure; eGFR  estimated
lomerular filtration rate; SBP  systolic blood pressure.ients were randomized to receive spironolactone (n  56)
r placebo (n  56). There were no significant clinical
ifferences between groups (Table 1). The cause of renal
isease was made by renal biopsy in 70% and by imaging in
3% of cases. A history of hypertension was documented in
2% of cases. Left ventricular hypertrophy on ECG voltage
riteria was present in 1 patient. Mean values for LV
jection fraction, volume, and mass were within normal
imits (20).
ollow-up. No patients died. Two patients did not com-
lete the follow-up period; 1 patient withdrew consent for
urther participation, and 1 patient had a relapse of Wege-
er granulomatosis causing acute renal failure. Two patients
ere hospitalized during their participation for unrelated
edical conditions.
reatment effects. HEMODYNAMIC, RENAL, AND ENDOCRINE
FFECTS. Compared with placebo, the use of spironolactone
esulted in a significant decrease in office systolic blood
ressure (11  12 mm Hg vs. 5  14 mm Hg, p 
.05) and pulse pressure (5  9 mm Hg vs. 1  9 mm
g, p  0.05). Central systolic blood pressure (12  12
m Hg vs. 4  14 mm Hg, p  0.01), central mean
rterial pressure (8  9 mm Hg vs. 4  10 mm Hg,
 0.05), and central pulse pressure (5  9 mm Hg vs.
1  8 mm Hg, p  0.01) also were reduced. Twenty-
our-hour ambulatory systolic blood pressure and pulse
ressure also decreased significantly in the spironolactone
roup (Table 2). Office, central, and ambulatory diastolic
ressures were not different between treatment groups
Table 2).
Compared with placebo, the use of spironolactone was
ot associated with a significant decrease in eGFR (spirono-
actone 3  7 ml/min/1.73 m2 vs. placebo 1  5
l/min/1.73 m2, p  NS). Treatment with spironolactone
educed albuminuria by 21  99 mg/mmol compared
ith 8  37 mg/mmol with placebo, p  0.05 (Table 2).
hanges in plasma aldosterone, plasma renin, plasma an-
iotensin II, and high-sensitivity C-reactive protein concen-
rations are shown in Table 2.
HANGES IN LV MASS, VOLUMES, AND FUNCTION. Compared
ith placebo, treatment with spironolactone resulted in
ignificant reductions in LV mass and LV mass index
Table 2, Fig. 1). The prevalence of LVH decreased by 50%
ith spironolactone but was unchanged with placebo (Table
). Baseline LV mass was not a predictor of LV mass
egression on multivariable analysis. The reduction in LV
ass index on spironolactone for those subjects with LVH
t baseline was8 8 g compared with6 5 g for those
ith a normal baseline LV mass (p  NS). Spironolactone
id not affect LV volumes or ejection fraction.
HANGES IN PWV, AORTIC DISTENSIBILITY, AND AUG IX. Com-
ared with placebo, the use of spironolactone resulted in a
ignificant decrease in PWV (Table 3, Fig. 2A), central
ortic pressure augmentation, Aug Ix, and Aug Ix 75 (Table
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Spironolactone in Early CKD August 4, 2009:505–12, Fig. 2B). Consistent with these changes, aortic distensi-
ility increased with the use of spironolactone compared
ith placebo (Table 3, Fig. 2C). All of the changes in
rterial stiffness remained significant after adjustment for
he reduction in mean blood pressure that occurred with
reatment (Table 3).
hanges in Blood Pressure, Laboratory, and CMR VariablesTable 2 Changes in Blood Pressure, Laboratory, and CMR Varia
Placebo
Week 0
24-h SBP (mm Hg) 125 10
24-h DBP (mm Hg) 77 8
Office SBP (mm Hg) 130 19
Office DBP (mm Hg) 77 10
Central SBP (mm Hg) 120 18
Central DBP (mm Hg) 78 10
ACR (mg/mmol)‡ 8.2 48.4
Renin (U/ml)‡ 87.0 103.5
Angiotensin II (pg/ml)‡ 8.0 16.5
PAC (pg/ml)‡ 67.0 49.3
hsCRP (mg/dl)‡ 1.08 3.85
LVEF (%) 72 8
LV mass (g) 110 26
LV mass index (g/m2) 59.2 11.3
LV hypertrophy (%) 8
LVEDV/BSA (ml/m2) 54 11
LVSV/BSA (ml/m2) 39 8
RVEDV/BSA (ml/m2) 64 12
RVEF (%) 61 6
p 0.01; †p 0.05. Normally distributed values are presented as mean SD; the remainder ‡w
hanges in the 2 groups, we used repeated measures analysis of variance with the time point
etween-subjects factor and tested the significance of the interaction between the 2.
ACR albumin/creatinine ratio; BSA body surface area; central DBP/SBP central aortic blo
ssessment; hsCRP  high-sensitivity C-reactive protein; LV  left ventricular; LVEDV  left ven
ass/body surface area; office DBP/SBP  brachial blood pressure recorded at hospital assessm
ight ventricular ejection fraction; other abbreviations as in Table 1.
Figure 1 Change in LV Mass and LV Mass Index in
Patients Treated With Spironolactone and Placebo
Data are mean  SEM. ††p  0.01 treatment by time
interaction, repeated measures analysis of variance. LV  left ventricular.cFFECT OF CHANGES IN BLOOD PRESSURE ON LV MASS AND
WV. The possible effects of the reduction in blood pressure
aused by spironolactone on the changes in LV mass and
WV were examined by determining the association of
hese changes with the changes in systolic pressure by the
se of multivariate regression models (Table 4). Indepen-
ent variables known to influence LV mass and arterial
tiffness were entered into the models. Only the change in
entral aortic systolic blood pressure was a significant
ndependent predictor of change in LV mass. The difference
n the strength of the association between the reduction in
entral aortic and ambulatory 24-h systolic pressures and
hange in LV mass is illustrated in Figure 3. When we
dded treatment with spironolactone to the model, the
ystolic blood pressure changes were rendered insignificant.
In a model with PWV as the dependent variable, the
hange in central systolic blood pressure (r2  0.28, p 
.01) and office systolic blood pressure (r2 0.28, p 0.01)
ere independent predictors and remained significant after
he addition of treatment with spironolactone to the models
r2  0.33 p  0.01 and r2  0.36, p  0.01, respectively).
dverse effects. During the open-label run-in phase, 1
atient with serious hyperkalemia (potassium 6.5 mmol/l)
as withdrawn, 1 patient with hypotension and acute
eterioration in renal function (eGFR decreased from 31 to
4 ml/min/1.73 m2) was withdrawn, and 1 patient withdrew
Spironolactone
ek 40 Week 0 Week 40
11 124 11 119 11*
7 76 8 73 8
17 130 16 119 13†
9 77 10 71 10
16 121 15 110 13*
9 78 10 72 10
34.9 17.8 48.6 5.4 34.9†
108.8 71.0 110.0 130.0 188.0*
13.7 8.0 16.7 14.2 41.0*
51.8 60.0 38.0 130.0 117.3*
2.06 2.22 3.49 2.33 3.64
7 69 8 72 9
28 119 34 105 30*
12.0 60.7 13.5 53.812.5*
8 11 5
12 56 13 53 11
8 38 7 38 8
14 66 12 64 12
6 59 7 59 6
transformed before comparison and are presented as median and interquartile range. To compare
0, week 40) as the within-subjects factor and the group (spironolactone and placebo) as the
sure derived using a validated transfer function (SphygmoCor, AtCor Medical) recorded at hospital
end-diastolic volume; LVEF  left ventricular ejection fraction; LV mass index  left ventricular
C  plasma aldosterone concentration; RVEDV  right ventricular end-diastolic volume; RVEF bles
We
124
76
125
73
116
74
9.5
74.5
7.8
43.5
1.38
72
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58.9
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59
ere log
(week
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tricularonsent. During the open-label run-in phase, 6 (5%) pa-
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August 4, 2009:505–12 Spironolactone in Early CKDients had potassium levels between 5.5 and 5.9 mmol/l and
ere switched to spironolactone on alternate days as per
rotocol. On blinded treatment between weeks 4 and 40, 4
atients had potassium levels between 5.5 and 5.9 mmol/l
hat required a dose reduction to alternate day treatment.
wo of these 4 patients were found to have been on placebo
fter the unblinding. After randomization, no patients were
ithdrawn because of hyperkalemia, and there were no
eported side effects, including gynecomastia. At week 40,
erum potassium was slightly greater in the spironolactone
roup than in the placebo group (4.6  0.6 mmol/l vs.
.4  0.4 mmol/l, p  0.05).
Figure 2 Changes in PWV, Aug Ix 75, and Aortic Distensibility
(A) Pulse-wave velocity (PWV), (B) augmentation index corrected for heart rate
of 75 beats/min (Aug Ix 75), and (C) aortic distensibility on cardiovascular
magnetic resonance in patients treated with spironolactone (Spiro) and pla-
cebo. Data are mean  SEM. †p  0.05; ††p  0.01 treatment by time inter-
action, repeated measures analysis of variance.
rterial Stiffness Values (Absolute and Corrected for Changes in MTable 3 Arterial Stiffness Values (Absolute and Corrected for C
P
Week 0
PWV (m/s) 8.3 1.7
Adjusted PWV
Aortic distensibility (103 mm Hg) 2.3 1.6
Adjusted aortic distensibility (103 mm Hg)
Augmentation (mm Hg) 12.9 8.8
Adjusted augmentation (mm Hg)
Aug Ix (%) 28.3 10.8
Adjusted Aug Ix
Aug Ix 75 (%) 25.1 10.9
Adjusted Aug Ix 75
alues aremean SD. Adjusted results are corrected for change inmean arterial pressure fromwe
ata for both groups combined. *p  0.01; †p  0.05 treatment by time interaction, repeated-m
Aug Ix  augmentation index; Aug Ix 75  augmentation index corrected for heart rate of 75 bseproducibility of measurements. There was good in-
raobserver agreement for the primary end points: LV mass:
 0.97 (112  22 g vs. 115  22 g, p  0.001), PWV:
 0.92 (7.2  1.6 m/s vs. 7.2  1.3 m/s, p  0.001).
iscussion
his randomized trial has demonstrated that important
tructural and functional cardiovascular abnormalities
ver Time by Linear Regression)es in MAP Over Time by Linear Regression)
o Spironolactone
Week 40 Week 0 Week 40
8.1 1.9 8.3 1.6 7.5 1.4*
8.3 1.9 7.9 1.5*
2.4 1.6 2.6 1.6 3.4 1.9*
2.4 1.6 3.4 1.8*
12.4 8.4 13.5 5.9 10.25.2 *
13.2 8.1 11.7 5.3*
27.9 10.1 30.8 10.8 26.2 9.5†
28.2 10.2 26.7 9.7†
23.4 10.1 25.6 9.6 20.6 9.2†
22.4 10.5 19.3 9.3*
0. Adjustments were based on coefficients obtained from linear regressions by the use of baseline
analysis of variance.
in; MAP  mean arterial pressure; PWV  pulse-wave velocity.
ultivariate Regression Models for thered ction of Change i Left Ventricular MassTable 4 Multivariate Regr ssion Models for thePrediction of Change in Left Ventricular Mass
No Treatment Effect
Included in Model
Treatment Effect
Included in Model
Model 1, r2 0.16 0.38
Change in BP
p value 0.05 0.15
Beta  SE 0.109 0.05 0.065 0.044
Treatment group
p value 0.01
Beta  SE 6.717 1.203
Model 2, r2 0.15 0.38
Change in BP
p value 0.08 0.19
Beta  SE 0.1 0.051 0.059 0.045
Treatment group
p value 0.01
Beta  SE 6.778 1.202
Model 3, r2 0.13 0.37
Change in BP
p value 0.21 0.72
Beta  SE 0.109 0.086 0.027 0.076
Treatment group
p value 0.01
Beta  SE 6.973 1.212
odel 1: age, sex, glomerular filtration rate (GFR), angiotensin-converting enzyme (ACE) inhibitor,
ngiotensin receptor blockers, calcium-channel blocker, beta-blocker, statins, change in central
ortic systolic blood pressure (BP)  treatment group. Model 2: age, sex, GFR, ACE inhibitor,
ngiotensin-receptor blockers, calcium-channel blocker, beta-blocker, statins, change in office
eripheral systolic BP  treatment group. Model 3: age, sex, GFR, ACE inhibitor, angiotensin-
eceptor blockers, calcium-channel blocker, beta-blocker, statins, change in 24-h ambulatoryAP Ohang
laceb
ek 0 to 4ystolic BP  treatment group.
Beta  unstandardized beta coefficient; SE  standard error.
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Spironolactone in Early CKD August 4, 2009:505–12resent in early stage CKD (3,24,25) can be improved by
ineralocorticoid receptor blockade. The addition of spi-
onolactone to established treatment with ACE inhibitors
r ARBs resulted in reduction in LV mass and improved
rterial stiffness along with reduced blood pressure and
lbuminuria. These effects occurred despite excellent blood
ressure control and a low prevalence of LVH at baseline.
hese findings provide further support for the importance
f aldosterone as a major cause of the development of
entricular hypertrophy and vascular and ventricular stiffness
n patients with early stage CKD. They also suggest that
ldosterone antagonism should be further evaluated in larger
rials as a possible powerful therapeutic option in the
reatment of this high-risk group of patients. Such trials
ould of course have to examine carefully the safety of such
reatment, most importantly the frequency of hyperkalemia.
his study was not large enough or of sufficient duration to
rovide reliable data on this outcome, but the incidence was
urprisingly low, which may have been due to the active
un-in phase and the exclusion of patients with diabetic and
enovascular CKD.
Although CKD is a major risk factor for atheromatous
oronary artery disease, it is now evident from epidemio-
ogical studies that heart failure and arrhythmias, arising as
he result of LVH and fibrosis, are the most common causes
f cardiovascular morbidity and mortality (2,26). Increased
rterial stiffness is a major factor in the development of
Figure 3 Changes in LV Mass Index
Shown are changes in left ventricular (LV) mass index associated with (A)
quartiles of central systolic blood pressure reduction and (B) quartiles of
ambulatory systolic blood pressure (SBP) reduction in patients randomized to
spironolactone. Data are mean  SD. ††p  0.01 trend between quartiles.VH, fibrosis, and ventricular dysfunction in patients with iKD, diabetes, and systolic hypertension (27–29). Thus,
ur finding that spironolactone can improve these funda-
ental pathophysiological abnormalities is of importance
nd suggests that treatment commenced early in CKD may
educe the later burden of adverse cardiovascular events.
Furthermore, there is increasing evidence that aldosterone
auses progressive renal injury in CKD; therefore, the use of
ldosterone antagonists has the potential to slow the progres-
ion of renal disease (6). This prevention of further decline in
enal function may have secondary benefits in the development
f cardiovascular disease in CKD because the magnitude of
isk is related to GFR. To date, beneficial effects of aldosterone
ntagonists on cardiovascular events and mortality have been
bserved in patients with heart failure, hypertension, and
yperaldosteronism but not in patients with CKD (30–33).
he use of aldosterone antagonists in CKD has been restricted
s the result of concerns about adverse effects on serum
otassium and renal function. Reported studies have been
mall without cardiovascular end points but have consistently
hown reductions in proteinuria and slowing of progression to
nd-stage kidney disease (34).
Reductions in LVH and arterial stiffness are associated
ith prognostic benefit in hypertension and CKD (35,36).
n the LIFE (Losartan Intervention For Endpoint) study
35), which examined hypertensive patients with LV hyper-
rophy, a reduction in LV mass index during 12 months of
1% was associated with a 15% reduction in relative risk of
ardiovascular events. In patients with end-stage CKD, a
0% reduction in LV mass achieved by multiple interven-
ions was associated with a hazard ratio of 0.72 for cardio-
ascular death (36). We have shown a similar reduction in
V mass by using spironolactone despite a “normal” mean
V mass on entry.
Our results are also similar to those of the 4E study (37),
n which the use of eplerenone and enalapril produced
dditive reductions in LV mass measured by CMR in
ubjects with LVH due to hypertension. Arterial stiffness is
strong prognostic marker in end-stage CKD, hyperten-
ion, and the general population; therefore, the vascular
nfluence of spironolactone may be beneficial independently
f changes in blood pressure or LV mass (38–40).
An important question raised by this study is the degree
o which the reductions in LV mass and arterial stiffness
which remained significant after mathematical correction
or the mean arterial pressure at which they were measured)
ere due to the effect of lowering systolic blood pressure
elative to the direct effects of mineralocorticoid receptor
lockade. Our use of an inactive placebo rather than a
ontrol antihypertensive agent means that we cannot provide a
efinitive answer to this question. The significant relationships
etween change in LV mass and PWV and the reduction in
entral aortic systolic blood pressure suggest that this be at least
art of the mechanism of action of spironolactone. The blood
ressure effects were much weaker than the treatment effect, so
t is plausible that blockade of cardiac and vascular mineralo-
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August 4, 2009:505–12 Spironolactone in Early CKDorticoid receptors reduced adverse effects of aldosterone such
s inflammation, fibrosis, and hypertrophy (41).
It is also possible that ACE-2 activity may have increased
nder the influence of spironolactone, leading to an increase
n angiotensin (1–7), which has vasodilatory, antifibrotic,
nd hypertrophic effects (42). Indeed, it is possible that the
eduction in systolic pressure that occurred with spironolac-
one was a result rather than a cause of reduced arterial
tiffness. In support of this theory is the finding that
plerenone treatment resulted in a reduction in the collagen/
lastin ratio and in vitro arterial stiffness of resistance
rteries in hypertensive patients (43). The lack of effect of
pironolactone on C-reactive protein provides no support
or an anti-inflammatory effect but does not exclude local
ffects on vascular inflammation. The significant associa-
ions between central aortic but not ambulatory blood
ressure changes and the improvements in LV mass and
WV are consistent with recent work showing that central
ut not peripheral pressures are determinants of clinical
utcome (12).
This study does not address whether maximizing doses of
CE inhibitors or ARBs would be as effective as adding 25 mg
aily of spironolactone to standard therapy, but all patients
ere on doses of ACE inhibitors and ARBs that achieved
lood pressure control for at least 6 months before recruitment.
he dose of 25 mg of spironolactone was chosen because this
ow dose is efficacious and safe in heart failure (when GFR is
ften reduced) (32) and because tolerability was demonstrated
n several small studies in CKD (34). We used peripheral blood
ressure for the calculation of aortic distensibility. We ac-
nowledge that central aortic blood pressure (measured by
pplanation tonometry) is the pressure “seen” by the LV and
orta, but because of the constraints of magnetic resonance
echnology, were not able to acquire this value at the time of
maging.
onclusions
n patients with early-stage CKD, the use of spironolactone
esulted in improvements in important prognostic markers
f cardiovascular disease; most of these effects were statis-
ically independent of the change in blood pressure. These
ata provide strong support for the further evaluation of
pironolactone in patients with CKD in trials with clinical
utcomes.
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